RxDoctor Payments Data

Roxana Siles, MD

Allergy & Immunology · Cleveland, OHNPI 1255518767

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,334 of the $5,580 with a category attached, or 77.7%. 10 manufacturers reported payments, led by AstraZeneca at 53.2% of the total. Reporting peaked in 2022 at $2,848 and has fallen 95.5% since, to $129 in 2025.

$5,580in general payments, 2019–2025

Across 21 payments — averaging $265.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • Regeneron Healthcare Solutions, Inc.$2K
  • Sanofi$279
  • CSL Behring$125
  • Phadia US Inc.$117
  • Teva Pharmaceuticals USA, Inc.$114
  • plus $209 from 4 others

What the payments were for

  • Consulting fees$4,33478%
  • Food & beverage$1,20422%
  • Education$431%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,580 in reported general payments places this provider in the 65th percentile of 128 allergy & immunology providers in Ohio.

See all allergy & immunology providers in Ohio

Medicare billing

Part B allowed, 2024
$22,360
Medicare patients
149
Services billed
224

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XolairOmalizumab49$234,913
CuvitruImmun Glob G(Igg)/Gly/Iga Ov5036$169,198
XembifyImmune Globulin,gamma(Igg)klhw33$128,067
NucalaMepolizumab24$84,118
Advair HfaFluticasone Propion/Salmeterol93$62,475
Breo ElliptaFluticasone/Vilanterol67$40,626
DuleraMometasone/Formoterol55$25,757
Incruse ElliptaUmeclidinium Bromide46$23,383
Arnuity ElliptaFluticasone Furoate63$18,420
Epinephrine52$11,846
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate29$9,451
Fluticasone-SalmeterolFluticasone Propion/Salmeterol76$9,045
SymbicortBudesonide/Formoterol Fumarate20$7,271
Azelastine Hcl205$5,746
AirsupraAlbuterol Sulfate/Budesonide11$4,806

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKNucala, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$95$166,548200 claims
AstraZenecaSymbicort, Airsupra$2,967$12,07731 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 128 allergy & immunology providers in Ohio.

Other allergy & immunology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →